21 September 2021 - interim results
The AIM-listed international healthcare group has continued its strong progress in the first half of 2021 with see-through revenues rising by 24% to £80.9m and underlying pre-tax profit up by the same amount at £20.1m. Earnings per share on the same basis were 22% higher at 2.99p and the interim dividend was raised by 5% to 0.563p. These are clearly impressive results although net debt remains high at £105.4m, down just £4m since December. Despite the solid results, the share rating does not leave much room for . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.